Commercial Products

Pipeline Information

Pipeline Information

About

Investor Relations

Newsroom

Language

F o r a B r i g h t e r
T o m o r r o w

Newsroom

All
Information
release
product

May 16, 2025Information

【Research Report】　Bridge Report　about Solasia

May 16, 2025Information

【Research report】　Shared research Q1 FY12/25 Flash Update

May 14, 2025Information

Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2025)

May 14, 2025Information

Consolidated Financial Results for the Three Months Ended March 31, 2025 (Under IFRS)

Mar 24, 2025Information

Solasia Announces Finance via Issuance of Warrant

Mar 05, 2025Information

Notice of the 17th Annual General Meeting of Shareholders

Feb 20, 2025Information

Announcement on Capital Reduction, Surplus Appropriation (Deficit Disposition), and Election of Directors and Auditor

Feb 12, 2025Information

Business Overview of Pipeline Products

Feb 12, 2025Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2024

Feb 12, 2025Information

Solasia Announces Booking of Impairment Loss and Difference Between Fiscal 2024 Consolidated Earnings Forecast and Actual Results

Jan 06, 2025Information

Solasia Announces Change in Sales Partner for episil in China

Jan 06, 2025Information

Solasia Provides Notice of Revision to Its Fiscal 2024 Earnings Forecast

Dec 27, 2024Information

Solasia Provides Notice of Revision to Full-Year Earnings Forecast and Progress on Out-Licensing DARVIAS in China

Dec 19, 2024Information

Research report about Solasia was updated by Shared Research Inc.

Nov 13, 2024Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2024 (under IFRS)

Nov 13, 2024Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2024)

Oct 25, 2024Information

（Delay）Results of important non-clinical studies of SP-05

Sep 27, 2024Information

Solasia Announces Notice of Status of Progress in Out-licensing SP-02 (DARVIAS) in China

Sep 26, 2024Information

IR Report：(Bridge-Salon)　about Solasia

Aug 14, 2024Information

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2024 (under IFRS)

Aug 14, 2024Information

Business Overview of Pipeline Products(Second Quarter of the Fiscal Year Ending December 31, 2024)

May 16, 2024Information

Research report about Solasia was updated by Shared Research Inc.

May 15, 2024Information

Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2024)

May 15, 2024Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2024 (under IFRS)

Apr 17, 2024Information

IR Report (Bridge Report) about Solasia

Mar 01, 2024Information

Notice of the 16th Annual General Meeting of Shareholders

Feb 19, 2024Information

Announcement Concerning Election of Five Board Directors and Two Audit & Supervisory Board Members

Feb 16, 2024Information

[Delayed] Solasia Announces Finance via Issuance of Unsecured Straight Bond and Warrant

Feb 14, 2024Information

Business Overview of Pipeline Products (The Fiscal Year Ending December 31, 2023)

Feb 14, 2024Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2023(under IFRS)

Jan 04, 2024Information

Research report about Solasia was updated by Shared Research Inc.

Dec 28, 2023Information

Solasia Announces Notice of Status of Progress in Out-licensing SP-02 (DARVIAS) in China and Revision of Full-year Earnings Forecast

Dec 22, 2023Information

Research report about Solasia was updated by Shared Research Inc.

Nov 13, 2023Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2023 (under IFRS)

Nov 13, 2023Information

Business Overview of Pipeline Products ( First Nine months of the Fiscal Year Ending December 31, 2023)

Oct 04, 2023Information

Solasia was selected as one of the top five biotech companies in Japan (by LIFE SCIENCE REVIEW) with products at the clinical stage and beyond.

Oct 04, 2023Information

IR Report (Bridge Report) about Solasia

Sep 06, 2023Information

An article introducing Solasia was published in Newsweek International magazine (September 6, 15 issue).

Aug 18, 2023Information

Shanghai New Office Notice

Aug 18, 2023Information

Reprint| The awarding ceremony of the first "Oral Mucositis (OM) Whole Process Management Model Ward" in China was successfully held

Aug 10, 2023Information

Business Overview of Pipeline Products ( First six months of the Fiscal Year Ending December 31, 2023)

Aug 10, 2023Information

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2023 (under IFRS)

Jun 26, 2023Information

Research report about Solasia was updated by Shared Research Inc.

Jun 16, 2023Information

Reprint| ASCO express | Bioadhesive barrier-forming oral gel- episil Effectively Ameliorates acute radiation dermatitis in patients with Breast Cancer

May 17, 2023Information

IR Report (Bridge Report) about Solasia

May 16, 2023Information

Research report about Solasia was updated by Shared Research Inc.

May 15, 2023Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2023 (under IFRS)

May 15, 2023Information

Business Overview of Pipeline Products ( First Quarter of the Fiscal Year Ending December 31, 2023)

Apr 07, 2023Information

Research report about Solasia was updated by Shared Research Inc.

Mar 20, 2023Information

SOLASIA HAS PARTNERED WITH WEP CLINICAL TO SUPPLY DARVIAS [DARVIAS Injection 135mg] UNDER A NAMED PATIENT PROGRAM

Mar 02, 2023Information

Notice of the 15th Annual General Meeting of Shareholders

Feb 20, 2023Information

Announcement Concerning Election of Five Board Directors and One Audit & Supervisory Board Member

Feb 14, 2023Information

Notice Regarding Recording of Impairment Loss (consolidated) and Extraordinary Loss (non-consolidated) for the Fiscal Year Ended December 2022

Feb 14, 2023Information

Business Overview of Pipeline Products (The Fiscal Year Ending December 31, 2022)

Feb 14, 2023Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2022 (under IFRS)

Dec 28, 2022Information

Research report about Solasia was updated by Shared Research Inc.

Nov 25, 2022Information

The final results of SP-05 arfolitixorin Phase III study

Nov 25, 2022Information

Solasia Announces Booking of Impairment Loss and Revision to Full-Year Earnings Forecasts

Nov 22, 2022Information

Solasia Announces Change in Largest Shareholder

Nov 14, 2022Information

Solasia Announces Revision to Full-Year Earnings Forecast

Nov 14, 2022Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2022 (under IFRS)

Nov 14, 2022Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2022)

Sep 05, 2022Information

Solasia Announces Summary of SP-04 PledOx Development Status

Aug 22, 2022Information

[Delayed] Solasia Announces Launch of Darvias in Japan

Aug 15, 2022Information

Business Overview of Pipeline Products (first six months of the Fiscal Year Ending December 31, 2022)

Aug 15, 2022Information

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2022 (under IFRS)

Aug 04, 2022Information

Solasia Announces Topline Data from Phase III AGENT Study of SP-05(arfolitixorin)

Jul 08, 2022Information

Solasia acquires episil oral liquid business from Camurus

Jun 30, 2022Information

License Transfer from Solasia to Lee’s Pharm for the Sales Promotion of Sancuso and episil in three cities in China

Jun 28, 2022Information

Solasia Announces Capital and Business Alliance with Nippon Kayaku Co., Ltd.

Jun 20, 2022Information

DARVIAS Injection 135mg (generic name: DARINAPARSIN /development code: SP-02) approved in Japan

May 13, 2022Information

Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2022)

May 13, 2022Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2022 (under IFRS)

May 12, 2022Information

Solasia announces SP-03 episil Business

Apr 25, 2022Information

Solasia’s Partner, Isofol announced start of study data analysis of SP-05 (arfolitixorin) phase III AGENT study

Apr 08, 2022Information

IR Report (Bridge Report) about Solasia

Mar 31, 2022Information

Research report about Solasia was updated by Shared Research Inc.

Mar 24, 2022Information

Notice of the Resolutions Adopted at the 14th Annual General Meeting of Shareholders

Mar 23, 2022Information

Solasia Announces Complete Redemption of Unsecured Straight Bond Issued total 500 Million JPY. (English pdf is not available.)

Mar 09, 2022Information

Notice of the 14th Annual General Meeting of Shareholders

Feb 21, 2022Information

Announcement of the matters to be resolved at the Ordinary General Meeting of Shareholders (March 24, 2022.)

Feb 14, 2022Information

Solasia Announces Finance via Issuance of Unsecured Straight Bond and Warrant

Feb 09, 2022Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2021 (under IFRS)

Feb 09, 2022Information

Business Overview of Pipeline Products (Fourth Quarter of the Fiscal Year Ended December 31, 2021)

Dec 28, 2021Information

Research report about Solasia was updated by Shared Research Inc.

Dec 10, 2021Information

[News] The history of research and development of SP-02 darinaparsin was published in the magazine of Texas A&M University

Nov 24, 2021Information

Solasia's Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer

Nov 24, 2021Information

Solasia's Partner, Isofol Receives FDA Fast Track Designation for arfolitixorin (SP-05) in Advanced Colorectal Cancer

Nov 10, 2021Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2021)

Nov 10, 2021Information

Solasia Announces Revision to Full-Year Earnings Forecast

Nov 10, 2021Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2021 (under IFRS)

Oct 26, 2021Information

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

Oct 26, 2021Information

Solasia Announces Change in Commercial Partner for SP-02 in Japan

Oct 13, 2021Information

IR Report (Bridge Report) about Solasia

Oct 12, 2021Information

Research report about Solasia was updated by Shared Research Inc.

Aug 11, 2021Information

Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2021)

Aug 11, 2021Information

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending December 31, 2021 (under IFRS)

Jul 27, 2021Information

Solasia’s website has been renewed

Jun 30, 2021Information

Solasia Announces Submission of New Drug Application for Anti-cancer Drug DARINAPARSIN for Peripheral T-Cell Lymphoma in Japan

Jun 30, 2021Information

Solasia Announces Exercise Price Revisions Associated with Series 12 Warrants

Jun 23, 2021Information

Research report about Solasia was updated by Shared Research Inc.

May 31, 2021Information

Solasia Announces episil was Recommended in Guidelines for Oral Mucositis Caused by Anti-tumor Therapy by CSCO

May 14, 2021Information

Solasia Announces Completion of Exercise of Series 11 Warrants

May 12, 2021Information

Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2021)

May 12, 2021Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2021 (under IFRS)

May 12, 2021Information

IR Report (Bridge Report) about Solasia

May 06, 2021Information

Solasia’s Partner, Isofol Announces Global Phase III AGENT Study for arfolitixorin(SP-05) Completed Recruitment of Japanese Patients

Mar 31, 2021Information

Solasia Announces Complete Redemption of Unsecured Straight Bond Issued total 2,500 Million JPY (English pdf is not available.)

Mar 29, 2021Information

Notice of the Resolutions Adopted at the 13th Annual General Meeting of Shareholders

Mar 22, 2021Information

Today’s Online Conference held by Isofol - Start at 22:00 JST (14:00 CET) on March 22

Mar 22, 2021Information

Solasia Announced iDSMB Recommended to Complete Global Phase III AGENT Study for arfolitixorin(SP-05) as Planned with 440 Patients

Mar 12, 2021Information

Notice of the 13th Annual General Meeting of Shareholders

Feb 26, 2021Information

Announcement Concerning Partial Amendment to the Articles of Incorporation and Election of Five Board Directors

Feb 10, 2021Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2020 (under IFRS)

Feb 10, 2021Information

Business Overview of Pipeline Products (Fourth Quarter of the Fiscal Year Ended December 31, 2020)

Jan 26, 2021Information

Solasia posted an analyst coverage webpage

Dec 15, 2020Information

Results from the Prematurely Closed PledOx(SP-04) POLAR Program

Dec 15, 2020Information

Solasia Announces Revision to Full-Year Earnings Forecast

Dec 10, 2020Information

Solasia’s Partner, Isofol Announces Global Phase III AGENT Study Has Recruited 440 Patients

Nov 13, 2020Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2020 (under IFRS)

Nov 13, 2020Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2020)

Oct 05, 2020Information

Solasia Announces Non-Clinical Research Results for ATL of DARINAPARSIN at Annual Meeting of Japanese Cancer Association

Sep 23, 2020Information

Solasia Announces episil oral liquid Launched in South Korea

Sep 04, 2020Information

【News】Following the result of SP-02 pivotal study, Dr. Zingaro, a compound inventor, emeritus professor of Texas A&M University and former M. D. Anderson Cancer Center chemist, was broadcast on TV in Texas, USA (Link to KBTX website)

Aug 13, 2020Information

Supplementary materials for Aug 13, 2020 announcement

Aug 13, 2020Information

Isofol and Solasia Enter License Agreement to Develop and Commercialize ARFOLITIXORIN in Japan

Aug 13, 2020Information

Solasia Announces Finance via issuance of Unsecured Straight Bond and Warrant

Aug 12, 2020Information

Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2020 (under IFRS)

Aug 12, 2020Information

Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2020)

Jul 15, 2020Information

Solasia Announces Option Agreement for New Drug Candidate with GeneCare Research Institute

Jun 15, 2020Information

Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study for Peripheral T-Cell Lymphoma

May 14, 2020Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2020 (under IFRS)

May 14, 2020Information

Business Overview of Pipeline Products (First Quarter of the Fiscal Year Ending December 31, 2020)

Apr 06, 2020Information

Update on SP-04 (PledOx) (3rd Report)

Mar 30, 2020Information

Notice of the Resolutions Adopted at the 12th Annual General Meeting of Shareholders

Mar 13, 2020Information

Notice of the 12th Annual General Meeting of Shareholders

Mar 02, 2020Information

PledPharma Announces Update on SP-04 (PledOx) Clinical Study Information

Feb 27, 2020Information

[Delayed] Announcement Regarding Changes to Executive Management and Conclusion of New Business Agreement with Itochu

Feb 13, 2020Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2019 (under IFRS)

Feb 13, 2020Information

Business Overview of Pipeline Products (Fiscal Year Ended December 31, 2019)

Jan 30, 2020Information

Solasia Announces Exclusive Out-Licensing Agreement for episil oral liquid with Synex in South Korea

Jan 23, 2020Information

PledPharma AB Announces Update on SP-04 (PledOx) Clinical Study Information

Jan 06, 2020Information

Solasia Selected as a Loan Margin Trading Issue

Dec 26, 2019Information

SOLASIA AND EDITFORCE ENTER INTO JOINT R&D AGREEMENT

Dec 16, 2019Information

GLOBAL PHASE III STUDY POLAR-A FULLY RECRUITED

Dec 10, 2019Information

Solasia Announces License and Capital Alliance for SP-04 (PledOx) with Maruho

Nov 13, 2019Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2019 (under IFRS)

Nov 13, 2019Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2019)

Oct 21, 2019Information

Solasia Announces Approval of episil oral liquid in South Korea

Oct 09, 2019Information

Solasia Announces Development Strategy for Expanded Indication of PledOx and Amendment of License Agreement

Sep 17, 2019Information

Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma

Aug 14, 2019Information

Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2019 (under IFRS)

Aug 14, 2019Information

Business Overview of Pipeline Products (Second Quarter of the Fiscal Year Ending December 31, 2019)

Jul 22, 2019Information

SOLASIA LAUNCHES EPISIL IN CHINA

Jul 01, 2019Information

Solasia Makes First Shipment of episil (SP-03) to China

Jun 27, 2019Information

Sancuso Newly Recommended in Guideline for Prevention and Treatment of Nausea and Vomiting Caused by Antitumor Therapies

May 15, 2019Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2019 (under IFRS)

May 15, 2019Information

Business Overview of Pipeline Products(First Quarter of the Fiscal Year Ending December 31, 2019)

Mar 29, 2019Information

Notice of the Resolutions Adopted at the 11th Annual General Meeting of Shareholders

Mar 18, 2019Information

SOLASIA LAUNCHES SANCUSO IN CHINA

Mar 14, 2019Information

Notice of the 11th Annual General Meeting of Shareholders

Mar 14, 2019Information

Solasia Files New Medical Device Application For episil in South Korea

Feb 27, 2019Information

Announcement Regarding Reduction in Amounts of Capital Stock & Legal Capital Surplus & Appropriation of Surplus & Election of Directors & Auditors

Feb 21, 2019Information

Rapid relief of pain in oral mucositis, New episil oral liquid approved in China

Feb 13, 2019Information

Consolidated Financial Results for the Fiscal Year Ended December 31, 2018 (under IFRS)

Feb 13, 2019Information

Business Overview of Pipeline Products (Consolidated Financial Results for the Fiscal Year Ended December 31, 2018)

Feb 04, 2019Information

Notice of Review Progress of episil oral liquid in China

Dec 26, 2018Information

Solasia Initiates Phase III program for PledOx in Japan

Dec 03, 2018Information

Notice of Guangzhou Office Opening

Nov 15, 2018Information

SP-01 Sancuso First Delivery

Nov 14, 2018Information

Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2018 (under IFRS)

Nov 14, 2018Information

Business Overview of Pipeline Products (Third Quarter of the Fiscal Year Ending December 31, 2018)

Sep 05, 2018Information

Announcement Regarding the Pricing for the Issuance of New Shares and Secondary Offering of Shares

Aug 28, 2018Information

Announcement Regarding Issuance of New Shares and Secondary Offering of Shares

Aug 17, 2018Information

Announcement Concerning Signing of License and Distribution Agreement for SP-02 (darinaparsin injection) in Latin America

Aug 17, 2018Information

[Delayed]Solasia acquires exclusive license to develop and commercialize episil (oral liquid) in South Korea

Aug 10, 2018Information

Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2018 (under IFRS)

Jul 24, 2018Information

Sancuso, the First Transdermal Patch for the Prevention of CINV Approved in China

Jun 29, 2018Information

Announcement Concerning Signing of Commitment Line Agreement

Jun 27, 2018Information

Notice of Review Progress of Sancuso in China

Jun 13, 2018Information

Announcement Concerning the Development Plan of PledOx

Jun 13, 2018Information

Announcement Concerning Signing of Commitment Line Agreement

May 16, 2018Information

episil (oral liquid) Launched in Japan

May 15, 2018Information

Consolidated Financial Results for the First Three Months of the Fiscal Year Ending December 31, 2018 (under IFRS)

Mar 30, 2018Information

Notice of the Resolutions Adopted at the 10th Annual General Meeting of Shareholders

Mar 15, 2018Information

Notice of the 10th Annual General Meeting of Shareholders

Mar 01, 2018Information

[Delayed] Consolidated Financial Results for the Fiscal Year Ended December 31, 2017 (under IFRS)

Feb 27, 2018Information

Announcement Regarding Change of Directors and Auditors

Feb 09, 2018Information

Summary of Financial Results 2017

Feb 09, 2018Information

Closing of Phase I Clinical Study of SP-04(PledOx)

Jan 24, 2018Information

Notice of Head Office Relocation

Dec 22, 2017Information

Notice Regarding Status of SP-01 and Revision to Financial Forecasts

Dec 06, 2017Information

[Delayed] Consolidated Financial Results for the Nine Months of the Fiscal Year Ending December 31, 2017 (under IFRS)

Nov 20, 2017Information

PledPharma and Solasia enter license agreement to develop and commercialize PledOx in Asia

Nov 14, 2017Information

Research report about Solasia is issued by Shared Research Inc.

Sep 05, 2017Information

[Delayed] Consolidated Financial Results for the Six Months of the Fiscal Year Ending December 31, 2017 (under IFRS)

Sep 04, 2017Information

IR Report (Bridge Report) about Solasia

Jul 07, 2017Information

Solasia Announces Approval of episil (oral liquid) in Japan

Mar 24, 2017Information

Solasia listed it’s shares to Tokyo Exchange Mothers

Feb 20, 2017Information

Approval for Listing of Shares of Solasia on the Tokyo Stock Exchange Mothers

Feb 16, 2017Information

Lee’s Pharmaceutical (HK) Limited and Solasia Pharma Announce License, Promotion and Supply Agreement for episil

Dec 05, 2016Information

Meiji Seika Pharma and Solasia Pharma Announce License and Collaboration Agreement for episil

Oct 12, 2016Information

Solasia files New Medical Device Applications for episil in Japan and China

Mar 28, 2016Information

Solasia initiates Phase II Study of Darinaparsin (SP-02L) for T-Cell Lymphoma

Nov 25, 2015Information

Lee’s Pharmaceutical (HK) Limited and Solasia Pharma Announce License, Promotional and Supply Agreement for Sancuso

Mar 30, 2015Information

Solasia acquires exclusive license and distribution rights from Camurus for episil oral liquid in Japan and China

Jan 19, 2015Information

Meiji Seika Pharma and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin Injection (SP-02)

Jul 31, 2014Information

ZIOPHARM and Solasia Pharma Announce Global License and Collaboration Agreement for Darinaparsin

Oct 26, 2011Information

Solasia Announces Initiation of Darinaparsin Injection(SP-02) Phase 1 Study

Mar 08, 2011Information

ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia

Mar 03, 2010Information

Solasia Pharma and Kyowa Hakko Kirin enter into a License Agreement for SP-01(Sancuso)in Asia

Jun 01, 2009Information

Sancuso clinical trial application filed in China

Oct 01, 2008Information

JapanBridge changes name to Solasia Pharma K.K. to reflect focus on asian strategy

Mar 23, 2008Information

JapanBridge (Current Solasia Pharma K.K.) and prostrakan partner to develop Sancuso in japan, China & parts of south east asia

See All

IR News

See All

Our Strength

Giving hope for the future
to everyone facing cancer.

Our goal is to listen to the voices of voiceless patients and use our expertise and creativity in order to take on difficult challenges and create new value beyond existing frameworks.

Specializing in oncology

Our deep expertise allows us to develop a wide range of pharmaceuticals to meet unmet medical needs.

In-depth understanding of patients

Solasia's in-depth knowledge in the field of drug development enables us to understand the “voices of voiceless patients,” identify the problems faced by patients and medical professionals, and use this knowledge to promote drug discovery.

Quick and flexible decision-making and response

Being a small, elite team, we can take on challenges that would be difficult for large companies to tackle thanks to quick decision-making, and deliver products thanks to flexible response capabilities.